Cancer immunotherapy Authors Stefano Vella Direttore, Dipartimento del Farmaco, Istituto Superiore di Sanità, Roma - Italy DOI: https://doi.org/10.33393/grhta.2016.305 Keywords: Immunoterapia, Cancer Abstract No abstract
Downloads PDF (Italian) ePub How to Cite Vella, S. (2019). Cancer immunotherapy. Global and Regional Health Technology Assessment, 3(Suppl. 1), S1-S2. https://doi.org/10.33393/grhta.2016.305 More Citation Formats ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver Download Citation Endnote/Zotero/Mendeley (RIS) BibTeX Issue Vol. 3 No. Suppl. 1 (2016): Suppl. 1 - Farmaci oncologici e sostenibilità Section Editorial (on invitation only) License Copyright (c) 2019 The authors This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Metrics Statistics Abstract views - 635 times PDF (Italian) downloads - 567 times ePub downloads - 225 times Sign up Browse Sections Health Technology Assessment Health Policies banners150 0.8 2023CiteScore 28th percentile Powered by Completed peer reviews since:November 4, 2020 Most popular articles in the last 30 days Economic and clinical burden associated with respiratory syncytial virus and impact of universal immunization with nirsevimab in Italy 162 Optimization in the HIV treatment: economic and organizational impact analysis of Bictegravir/Emtricitabine/Tenofovir Alafenamide 152 Value contribution of leniolisib in the Treatment of Activated PI3Kδ syndrome (APDS) in Spain using Multi-Criteria Decision Analysis (MCDA) 147 Assessing the economic burden of Waldenström’s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL), and Chronic Lymphocytic Leukemia (CLL) 142 Towards a Green Health Technology Assessment: embedding Life Cycle Assessment for sustainable choices 140